Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome

Roberta Fenoglio, Savino Sciascia, Giulietta Beltrame, Paola Mesiano, Michela Ferro, Giacomo Quattrocchio, Elisa Menegatti, Dario Roccatello, Roberta Fenoglio, Savino Sciascia, Giulietta Beltrame, Paola Mesiano, Michela Ferro, Giacomo Quattrocchio, Elisa Menegatti, Dario Roccatello

Abstract

Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome (NS) cases. Adult-MCD patients may have more severe clinical features than pediatric patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In adults, data about the efficacy of RTX for MCD are limited. We report our experience on the use of RTX in adult biopsy-proven MCD. Our series includes 6 adult patients (2 males and 4 females), age 45-73 years, treated with RTX (4 weekly doses of 375 mg/m2). Proteinuria decreased from 11,2 (23-4.8) g/24 hours to 0.6 (0-2) g/24 hours after 6 months, and to 0.4 (0-1, 4) g/24 h in the 4 pts with the longer follow-up. Creatinine decreased from 1.95 (0.5-5) mg/dl to 0.88 (0.6-1.3) mg/l. Five patients achieved a complete renal remission, while in 1 pt proteinuria decreased by 75%. RTX successfully depleted CD19 lymphocytes in 100% of pts for at least 6 months. No clinically relevant adverse events have been observed. This case series shows a remarkable efficacy of RTX in treatment of MCD. RTX can be an attractive alternative both in recurrent forms and in induction-therapy of MCD. RTX may be preferentially used in patients at a high risk of development of the adverse effects of corticosteroids and should be considered as an alternative option in patients with recurrent NS. Additional data are needed to inform clinical practice on how best to use RTX in this patient population, so that definitive randomized trials can be planned.

Keywords: CD20; Immunology; adult minimal change; monoclonal antibody; nephrotic syndrome; rituximab.

Conflict of interest statement

CONFLICTS OF INTEREST As regards the submitted paper, the authors declare no conflict of interest and no financial support from any organization that might have an interest in the results of the present study.

Figures

Figure 1. Evolution of proteinuria
Figure 1. Evolution of proteinuria

References

    1. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: A long-term follow-up. Kidney Int. 1986;29:1215–1223.
    1. Van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci. 2004;2:125–36.
    1. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445–53.
    1. Palmer SC, Nand K, Strippoli GF. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2008;23:CD001537.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group KDIGO Clinical Practice Guidelines for Glomerulonephritis. Kidney International Supplements. 2012;2:139.
    1. Maas RJ, Deegens JK, Beukhof JR, Reichert LJ, Ten Dam MA, Beutler JJ, van den Wall Bake AWL, Rensma PL, Konings CJ, Geerse DA, Feith GW, Van Kuijk WH, Wetzels JF. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. Am J Kidney Dis. 2017;69:637–646.
    1. King C, Logan S, Smith SW, Hewins P. The efficacy of rituximab in adult frequently relapsing minimal change disease. Clin Kidney J. 2017;10:16–19.
    1. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49:239–48.
    1. Li X, Xu N, Li H, Han F, Wang R, He Q, He X, Chen J. Tacrolimus as rescue therapy for adult-onset refractory minimal change nephrotic syndrome with reversible acute renal failure. Nephrol Dial Transplant. 2013;28:2306–12.
    1. Trompeter RS. Minimal-change nephrotic syndrome and cyclophosphamide. Arch Dis Child. 1986;61:727–9.
    1. Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol. 2011;24:203–7.
    1. Fujinaga S, Hirano D, Murakami H, Ohtomo Y, Shimizu T, Kaneko K. Nephrotoxicity of once-daily cyclosporine A in minimal-change nephrotic syndrome. Pediatr Nephrol. 2012;27:671–4.
    1. Ramachandran R, Kumar DAP, Nada R, Jha V, Gupta KL, Kohli HS. Chronic nephrotoxicity limits successful use of Tacrolimus in the management of adult steroid-dependent minimal change disease. Nephrology. 2015;20:384–5.
    1. Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant. 2007;22:2100–2.
    1. Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, Fenoglio R, Baldovino S, Menegatti E. The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 year observation study. Oncotarget. 2017;8:52072–52077. doi: 10.18632/oncotarget.18120.
    1. Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12:854–9.
    1. Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, et al. Mentor Consortium group A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR) Nephron. 2015;130:159–68.
    1. Roccatello D, Sciascia S, Di Simone D, Solfietti L, Naretto C, Fenoglio R, Baldovino S, Menegatti E. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. Autoimmun Rev. 2016;15:529–38.
    1. Fenoglio R, Naretto C, Basolo B, Quattrocchio G, Ferro M, Mesiano P, Beltrame G, Roccatello D. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res. 2017;65:186–192.
    1. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschênes G, Ronco PM, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83:511–6.
    1. Takei T, Nitta K. Rituximab and minimalchange nephrotic syndrome: a therapeutic option. Clin Exp Nephrol. 2011;15:641–7.
    1. Yokoyama H, Kida H, Tani Y, Abe T, Tomosugi N, Koshino Y, Hattori N. Immunodynamics of minimal-change nephrotic syndrome in adults T and B lymphocyte subsets and serum immunoglobulin levels. Clin Exp Immunol. 1985;61:601–7.
    1. Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int. 2017;92:227–237.
    1. Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Simoncini M, Menegatti E. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14:1123–30.
    1. Roccatello D, Sciascia S, Rossi D, Solfietti L, Fenoglio R, Menegatti E, Baldovino S. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget. 2017;8:41764–41777. doi: 10.18632/oncotarget.16986.
    1. Datta SK. Anti-CD20antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol. 2009;5:80–2.
    1. Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, Jordan SC, Yap HK. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol. 2007;18:476–85.
    1. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005;44:176–82.
    1. Kim JE, Park SJ, Ha TS, Shin JI. Effect of rituximab in MCNS: a role for IL-13 suppression? Nat Rev Nephrol. 2013;9:551.
    1. Sentís A, Diekmann F, Llobell A, de Moner N, Espinosa G, Yagüe J, Campistol JM, Mirapeix E, Juan M. Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. Immunobiology. 2017;222:620–630.
    1. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, et al. Rituximab targets podocytes in recurrent focal-segmental glomerulosclerosis. Sci Transl Med. 2011;3:85.
    1. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539–44.
    1. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood—follow-upafterCD19recovery. Nephrol Dial Transplant. 2012;27:1083–9.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner